SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

A day at ECRI Institute's medical device testing laboratory Exploring three topics hospital execs need to know about

7 Tesla MR shows promise in first-of-its-kind cardiac study Yields value in diagnosing hypertrophic cardiomyopathy

Jury rules Philip Morris won’t have to cover chest CT scans for smokers Would have cost tobacco giant about $5 million annually

Britain's junior doctors striking in contract dispute Doctors say government rejected 'fair' offer

Hospitals are participating in fewer health insurance networks in 2016 New research suggests it may be part of normal market evolution

Against the odds, Princeton Baptist cardiologist saves patient's life First-of-its-kind 20 hour procedure conducted on massive aneurysm

Philips and Validic aim to combine fitness data with the EHR Adding medical value to consumer wearables

Optical Coherence Tomography scanner a boon to basal-cell diagnosis VivoSight OCT may lead to a future with fewer biopsies

With Avicenna, IBM Watson Health interprets radiology images Commercialization preparations are just beginning

Are low dose radiation concerns based on bad science? Loyola research team thinks so Examining the harmful side of dose preoccupation

CMS panel says evidence lacking for Amyvid

By Brendon Nafziger and Loren Bonner

A Medicare advisory panel voted Wednesday there wasn't enough evidence to determine whether the PET amyloid drug Amyvid could help improve outcomes for patients with early signs of cognitive dysfunction. The decision by the panel, called the Medicare Evidence Development & Coverage Advisory Committee, could represent a setback in efforts to get national Medicare coverage for the drug, and potentially others that will be coming down the pipeline for amyloid PET imaging.

Story Continues Below Advertisement

Zetta Offers Used CT & MRI, Multislice PET/CT Systems, Service & Parts

Zetta is a high performance independent service organization offering preowned / used medical equipment, dedicated CT & MRI service and quality replacement parts to the medical imaging industry. Phone: 847-550-9990 Email: Sales@zettamed.com



The MEDCAC panel only judged evidence for the drug and has no authority to determine if Amyvid should be covered. However, the Center for Medicare and Medicaid Services relies on its advice to inform coverage decisions for new technology or procedures — in this case, with Amyvid for PET beta-amyloid imaging.

The Eli Lilly & Co. drug received FDA approval last spring. It's used in PET scans to help doctors measure beta-amyloid plaque load in the brain, which is associated with Alzheimer's disease.

According to the language of Amyvid's FDA approval, a positive scan is not diagnostic for Alzheimer's, but a negative scan could help physicians rule out the brain-wasting disease in favor of other types of dementia.

Backers of the agent say it can help change management of patients, but a majority of the expert panelists, made up of radiologists, neurologists and psychiatrists, thought the jury was still out on the drug.

"I just can't connect the dots between the current state of knowledge of the way the test performs and the outcome," Dr. Steve Gutman, a panelist and strategic advisor with Myraqa Inc., said at the meeting. "I don't think you can create a chain of evidence here that works."

In the vote, the panelists gave their confidence rating on the evidence an average of 2.2 on a five point scale, indicating lower levels of confidence. The panel also voted that the uncertainty applied to Medicare-aged populations, too.

"I think it's incredibly important to our patients and our physicians to have a biomarker like this available," said Dr. Jerrold Rosenbaum, the psychiatrist-in-chief at Massachusetts General Hospital. "The question is, this one and now, not whether we need it (in general)."

Skeptics on the panel said they wanted more studies that include enough patients with unexplained mild cognitive impairment, thought to benefit most from the scans, and they also wanted proof that the drug actually changed patient management.

The panel also expressed concern about potential overuse of the scans and the danger that false positives — positive scans of actually healthy people — could needlessly worry patients. "I'm not sure I have enough data to be able to weigh the benefits and harms of this particular technology in terms of that false positive aspect," Dr. Art Sedrakyan, an associate professor at Weill Cornell Medical School and vice-chair of the panel, said.

Continue reading CMS panel says evidence lacking for Amyvid ...
  Pages: 1 - 2 >>

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.
ALL RIGHTS RESERVED